Description
The parental continuous cell line HELA was established from the primary cervix carinoma of a 31-year-old black woman 1951; KB-3-1 is a derivative of HELA and is used in multiple drug resistance studies giving raise to drug-resistant mutants (e.g. KB-V1 resistant to vinblastine; KB-CHR-8-5 resistant to colchicine); cells express MYC mRNA; the cell line will only be distributed to non-profit institutions, commercial entities may apply for a license at the NIH/NCI Technology Transfer Cernter, Rockville, MD, USA, phone (301)435-3111
Source
cervix carcinoma (derivative of HELA)
Culture Properties
monolayer
Morphology
epithelial-like, adherent cell line growing in monolayers
Karyotype
Human hypertriploid karyotype with 1.8% polyploidy - 76(73-78)<3n>XX, -X, -1, -3, -4, +6, +7, +8, -9, -18, -20, +11mar, der(1)t(1;?)((p11;?), der(3)t(3;?)(p11;?), der(3) t(3;?)(p14;?), der(3p;5q), del(6)(q21), del(7)(q31), der(8)t(8;?11) (q24;q11), der(9)
Quality Control
Mycoplasma: negative in DAPI, microbiological culture, RNA hybridization, PCR assays
Immunology: cytokeratin +, cytokeratin-7 -, cytokeratin-8 +, cytokeratin-17 +, cytokeratin-18 +, desmin -, endothel -, GFAP -, neurofilament -, vimentin +
Viruses: ELISA
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 1 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no.
If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon.
USA: 1-631-626-9181
Europe: 44-208-144-6005
